Market Overview

UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical Ahead of GALNS Data

Share:
Related BMRN
Is BioMarin Still An Outperform At This Research Firm?
BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
After Hours Gainers / Losers (Seeking Alpha)

Jefferies reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $44 to $46.

Jefferies said, "Our experts discussions indicate probability of successful GALNS Ph3 for Morquio A syndrome (MPS IV) at ~60%-85%. If successful, we forecast ~25-30% upside from current levels (& BMRN will likely continue to trade up on additional pipeline potential). BMRN expects GALNS BLA filing in 1Q13, with potentially regulatory approval by 4Q13. We forecast GALNS to turn BMRN to profitability, with peak annual sales potential of ~$500M."

BioMarin Pharmaceutical closed at $38.87 on Tuesday.

Latest Ratings for BMRN

DateFirmActionFromTo
May 2015JP MorganMaintainsOverweight
Mar 2015JefferiesMaintainsBuy
Feb 2015CitigroupMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters